Founded in 2014, Yunqi Partners is among the first in China to sharpen its focus on technology empowered industries. Yunqi is systematically investing in digital transformation of industries and industrialisation of technologies covering areas such as cutting-edge technology, advanced manufacturing, IoT, SaaS and B2B supply chain.

Yunqi Partners

5Y Capital is a firm engaged in providing early-stage venture investments. It was formerly known as Morningside Venture Capital. The investment firm manages USD 5bn in dual-currency funds in USD and RMB, backed by world-renowned sovereign wealth funds, family offices, fund of funds, university endowments, pensions, and foundations. It was headquartered in Xuhui, Shanghai, China in 2008 by Ken Shi and Richard Liu.

5Y Capital

Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special funds and have invested 7 billion RMB into  388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises. GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.

Green Pine Capital Partners

Eminence Ventures is a venture capital firm.

Eminence Ventures

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies. Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Hillhouse Investment

Trustbridge is a growth-oriented private equity firm with offices in Boston, Shanghai, and Hong Kong. The firm invests globally in innovative, high quality growth opportunities in various stages across Technology, Healthcare and Media. Founded and managed by entrepreneurs and operators, Trustbridge provides patient, long-term capital and partners with management teams building products and services that improve lives globally. Utilizing a growing, global portfolio and deep operational expertise, the firm has a particular focus on helping its portfolio companies enter new international markets, including China.

Trustbridge Partners

Pavilion Capital Partners is a growth-oriented private equity investor. It provides capital and strategic support to companies in the United States and Asia. In particular, the focus is on industries experiencing high growth due to globalization, technology, or demographic trends.  It actively works with company founders/management to assist in strategic initiatives, mergers and acquisitions, and eventual liquidity. The pavilion is partnered with family offices and private equity funds and is based in New York City.

Pavilion Capital

Prosperity7 Ventures is a venture capital firm that invests in early and growth-stage startups with a long-term view. The firm investments range from early-stage enterprise, blockchain, financial and industrial technologies to medical and healthcare solutions. industries as diverse as MedTech, fintech, and B2B SaaS. They provide venture funding that presents an unparalleled opportunity for international scalability and impact.

Prosperity7 Ventures

Zilliz

Zilliz is a leading vector database company for enterprise-grade AI. Built by the engineers behind Milvus, the world's most popular open-source vector database, Zilliz is on a mission to unleash data insights with AI. The company builds next-generation database technologies to help organizations rapidly create AI/ML applications, and unlock the potential of unstructured data. By taking the burden of complex data infrastructure management off of its users, Zilliz is committed to bringing the power of AI to every corporation, every organization, and every individual. Headquartered in San Francisco, Zilliz is backed by a number of prestigious investors, including Hillhouse Capital, Aramco's Prosperity7 Ventures, Temasek's Pavilion Capital, 5Y Capital, Yunqi Partners, Trustbridge Partners and others. Zilliz's technologies and products help over 1000 organizations worldwide easily create AI applications in various scenarios, including computer vision, image retrieval, video analysis, NLP, recommendation engines, targeted ads, customized search, smart chatbots, fraud detection, network security, new drug discovery, and much more. Learn more at zilliz.com or follow @zilliz_universe.

<div>Based in China, Zilliz specializes in vector database and AI technologies. The company&rsquo;s flagship open-source unstructured data service, Milvus, can analyze large unstructured data in the form of images, videos, chemical structures, and gene sequences. It is being used by more than 5,000 enterprises for various applications, including new drug development and gene analysis.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Zilliz is a provider of vector databases for AI applications. The company has two main products: Zilliz Cloud and Milvus. Zilliz Cloud is a fully-managed vector database service known for its speed, scalability, and performance. Zilliz Cloud serves various AI applications, including product recommendations, semantic text search, targeted advertising, risk control, and fraud prevention. It has a vector-native architecture suitable for LLMs and can be integrated with ChatGPT through OpenAI plugins. This enables LLMs to expand their knowledge by accessing additional data sources while reducing hallucinations.

Empowering Tomorrow's Innovations with Generative AI Infrastructure

Generative AI Infrastructure

Zilliz Named a Leader in Vector Database Providers by Forrester Wave Report

<div>
 
 Based in China, Zilliz specializes in vector database and AI technologies. The company&rsquo;s flagship open-source unstructured data service, Milvus, can analyze large unstructured data in the form of images, videos, chemical structures, and gene sequences. It is being used by more than 5,000 enterprises for various applications, including new drug development and gene analysis.
 
 
 The company&rsquo;s product lineup includes Zilliz Cloud, a fully-managed vector database service, and other tools designed to facilitate AI-powered search and data processing. The company operates a B2B business model offering its solutions on a subscription basis, starting at USD 65 per month. 
 
 
 Key customers and partnerships
 
 
 As of March 2024, Zilliz reported over 11 million downloads. The company&rsquo;s key customers include global companies such as eBay, Microsoft, Walmart, Ikea, IBM, and Regeneron.
 
 
 Funding and financials
 
 
 In 
 <a href="https://www.businesswire.com/news/home/20220824005057/en/Vector-Database-Company-Zilliz-Raises-60-Million-Series-B-Extension-to-Expand-Its-Operations-in-Silicon-Valley">
 August 2022
 </a>
 , Zilliz raised USD 60 million in a Series B extension round led by Prosperity7 Ventures. The funds were expected to be used for expanding Zilliz's engineering and go-to-market teams, particularly after establishing its headquarters in Silicon Valley. 
 
</div>

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Zilliz is a provider of vector databases for AI applications. The company has two main products: Zilliz Cloud and Milvus. Zilliz Cloud is a fully-managed vector database service known for its speed, scalability, and performance. Zilliz Cloud serves various AI applications, including product recommendations, semantic text search, targeted advertising, risk control, and fraud prevention. It has a vector-native architecture suitable for LLMs and can be integrated with ChatGPT through OpenAI plugins. This enables LLMs to expand their knowledge by accessing additional data sources while reducing hallucinations.Milvus is Zilliz Cloud’s open-source counterpart and is an open-source vector database that enhances similarity search for unstructured data and supports AI applications. The Milvus vector database utilizes deep learning algorithms and its proprietary AI model to efficiently generate, store, index, and organize vectors to improve data classification. It graduated from the Linux Foundation Incubator in June 2021 and is designed for efficient similarity searches in large vector datasets. Milvis has in excess of 10 million downloads and 25,000 GitHub stars as of January 2024.The Zilliz platform is offered through a SaaS subscription model, including a free version for the Starter package, USD 65 per month for the Standard package, and USD 99 per month for enterprises (March 2024).In <a href="https://sp-edge.com/updates/33468">September 2024</a>, Zilliz launched a&nbsp; major upgrade to Zilliz Cloud to address challenges in scaling GenAI applications from prototype to production.Key customers and partnershipsZilliz’s customer base includes notable names across retail, telecom, and Big Tech, including eBay, AT&amp;T, Walmart, IKEA, NVIDIA, IBM, and PayPal.Notably, Zilliz has partnered with AWS to offer Zilliz Cloud on AWS, thus increasing access to developers for tools for building AI-powered applications while simplifying integration with other AWS AI and ML technologies.

<div>
 
 Founded in Israel, NeuReality specializes in providing hardware infrastructure to streamline computation processes to accelerate the development of AI applications. Its technology assists AI inferencing deployment by offering a comprehensive system solution that seamlessly supports a vast array of deep learning models.
 
 
 NeuRealitys&rsquo; infrastructure includes an architecture called the Network Addressable Processing Unit (NAPU) to maximize the capabilities of Deep Learning Accelerators (DLAs). This design facilitates inference through purpose-built NAPUs that are specifically crafted for AI inference tasks, enhancing performance and efficiency.
 
 
 The NR1 AI Inference Solution by NeuReality is a comprehensive system comprising architecture, hardware, and software platforms. Launched in November 2023, it intends to simplify the installation, utilization, and management of AI, making it accessible and manageable for users.
 
 
 The hardware offerings of the solution include,
 
 
 1. 
 NR1 Network Addressable Processing Unit
 : A network addressable inference Server-on-a-Chip with an embedded Neural Network Engine, which is a workflow-optimized hardware device with specialized processing units, native network capabilities, and virtualization capabilities
 
 
 2. 
 NR1-M&trade; AI Inference Module
 : A full-height, double-wide PCIe card containing one NR1 Network Addressable Processing Unit (NAPU) system-on-chip and a network addressable Inference Server that can connect to an external Deep Learning Accelerator (DLA)
 
 
 3. 
 NR1-S AI Inference Appliance
 : An optimized design for an inference server that contains NR1-M modules with the NR1 NAPU, which enables disaggregated AI service in a scalable and efficient architecture
 
 
 The software component of the solution is designed to be compatible with any trained model from any development environment. It includes tools that handle the entire AI pipeline and enable seamless connection of AI workflows to any environment.
 
 
 NeuReality differs from traditional AI chip connectivity in replacing CPU-centric support with an AI-centric platform. This allows components to communicate directly with AI accelerators, eliminating the need for commands to pass through a central processing unit. Additionally, the technology enables AI accelerators to connect with each other, enhancing efficiency and performance in AI applications. It also claims its AI-centric approach reduces complexity, cost, and power usage. The firm claims it can reduce inference costs by 90%.
 
 
 Key customers and partnerships
 
 
 In November 2021, NeuReality teamed up with IBM to develop advanced AI inference technology by enhancing its NR1 chip and system for use in IBM's Hybrid Cloud.
 
 
 In September 2021, the company partnered with Xilinx to develop AI-centric platforms that improve real-world AI applications. This collaboration was intended to focus on NeuReality's AI-centric inference platform NR1-P and address existing issues with AI deployment including cost and complexity.
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27745">
 March 2024
 </a>
 , NeuReality secured USD 20 million in funding led by The European Innovation Council (EIC) Fund. The funds were intended to accelerate the deployment of NeuReality&rsquo;s NR1AI Inference Solution.
 
 
 In December 2022, it secured USD 35 million in a Series A funding round led by Samsung Ventures, with Cardumen Capital, Varana Capital, OurCrowd, XT Hi-Tech, and others as participants. The funding was used to launch its flagship AI inferencing solution.
 
</div>

NeuReality

<div>
 
 Accubits is an AI and BLOCKCHAIN focused development and solutions company based in Washington DC with its development offices in India and Dubai. Pioneering as a custom Blockchain solutions provider delivering solutions ever since 2012, Accubits is one of the oldest and experienced Blockchain dev house in the market and is featured as one among the top 13 Blockchain companies in India by INC42. We are a big family of engineers, innovators, inventors and many others continually working to help our customers in leveraging their business and adding value to their lives. Over the past 6 years, We have delivered more than 600 projects, for over 200 clients worldwide. Several of Fortune 500 companies in sectors from Retail to Health are being powered by our solutions to streamline and leverage their growth.Our portfolio for AI solutions includes intelligent conversational tools, RPAs, CRMs, SIPs, real-time video and image analytics systems, state of the art ALPR systems and many more being used enterprises, startups across North America, Canada, Middle East, Hong Kong, Singapore, Indonesia, India &amp; Sweden. Our portfolio of Blockchain development includes custom DApps and smart contracts, crypto token and exchange development, integrated blockchain services and ICO platforms.
 
</div>

Accubits

<div>
 
 LeewayHertz is a leading software development company delivering tailor-made digital solutions to businesses worldwide. Our team of 250+ full-stack developers, designers and innovators has designed and developed 100+ digital solutions across industry verticals. As a close-knit team of AI and web3 experts, designers and full-stack developers, we undertake collaborative research and development to create next-gen applications and solutions perfectly suited to the evolving tech space. As a technology pioneer with deep knowledge and expertise in AI, blockchain and other advanced technologies like IoT, LeewayHertz believes in helping companies overcome their most complex tech challenges and drive business growth. Our motto, &lsquo;You Dream It: We Build It,&rsquo; reflects our business philosophy. From putting flesh on your idea to delivering the expected end product, we do whatever it takes to make your project successful. Having worked with 30+ top fortune 500 companies and created various on-demand solutions, we boast an impressive work portfolio demonstrating our expertise.
 
</div>

LeewayHertz

Databricks, a data and AI company established by the original developers behind prominent Big Data solutions such as Delta Lake, Apache Spark, and MLflow, and provides organizations with AI and data analytics tools for efficient management of their data.Databricks' primary product is the Databricks Lakehouse platform, a unified data intelligence platform that merges a data warehouse and data lake to provide developers with efficient access to data and enables enterprise customers to create their AI models—similar to a ChatGPT-style AI system—using only their internal data.Databricks Unity Catalog, part of the Databricks Lakehouse Platform, provides unified governance for structured and unstructured data, machine-learning models, notebooks, dashboards, and files across various environments, offering automated monitoring, proactive alerts, and seamless data sharing through Delta Sharing integration. Furthermore, Databricks offers an open architecture that streamlines the AI development process, allowing the integration of various LLMs such as Llama 2, Azure OpenAI, and Anthropic, enabling customization with enterprise data for tailored model creation.Notably, Lakehouse leverages NVIDIA technology for accelerated data processing and AI model generation. Databricks also offers industry-specific solutions like Databricks Lakehouse for Healthcare, Financial Services, Retail, and Manufacturing.Databricks has expanded its offerings through multiple acquisitions, including MosaicML ( <a href="https://sp-edge.com/updates/19683">July 2023 </a>), Arcion ( <a href="https://sp-edge.com/updates/23041">October 2023 </a>), Okera ( <a href="https://sp-edge.com/updates/18197">May 2023 </a>), and Datajoy (October 2022). Key customers and partnershipsAs of July 2023, Databricks served a global customer base of approximately 10,000, including notable customers such as Comcast, DuPont, Honeywell, Rolls-Royce, Shell, and Tata Steel.Notable partnerships include collaboration with NVIDIA to incorporate NVIDIA TensorRT-LLM into its inference service and a partnership with Hevo-Data to automate data integration into the lakehouse for mutual customers (October 2022).Databricks also partnered with Karini AI to accelerate GenAI deployment for enterprises (<a href="https://sp-edge.com/updates/33687">September 2024</a>)Databricks also provides an LLM Mesh partner program; it has partnered with firms such as <a href="https://sp-edge.com/updates/24218">Dataiku </a>where an emphasis is placed on comprehensive data access, enabling tight integration of GenAI applications with enterprise data.

Databricks

<div>
 
 Labelbox offers a data-centric AI platform for enterprises, enabling them to develop, optimize, and use AI to solve complex problems and power new products and services.&nbsp;&nbsp;
 
 
 Labelbox&rsquo;s platform offers capabilities for building, optimizing, training, fine-tuning LLMs, and AI-enabled data labeling automation.&nbsp;
 
 
 Its products include&nbsp;
 
 
 1) Catalog: A platform for building AI applications with features such as advanced search capabilities and optimizing data for labeling budgets
 
 
 2) Annotate: A data labeling solution designed to streamline and accelerate labeling operations using automation tools and pre-labeling techniques
 
 
 (3) Model: Offers tools for data enrichment, model-assisted labeling, and custom Foundry Apps to automate data management tasks and improve AI model performance&nbsp;&nbsp;
 
 
 (4) Boost: Offers fully managed tailored solutions such as on-demand data labeling services to enhance AI development speed and efficiency.&nbsp;
 
 
 As such, Labelbox enables companies to streamline the fine-tuning and alignment of LLMs and enables the validation of outputs through techniques such as reinforcement learning with human feedback (RLHF), reinforcement learning from AI feedback (RELIEF), and evaluation. This incorporation of human expertise ensures more accurate, contextually relevant, trustworthy, and secure results from LLM systems.
 
 
 The platform is offered through a SaaS subscription model with packages ranging from free subscriptions with limited usage and custom pricing for enterprises.
 
 
 Key customers and partnerships
 
 
 The firm's solutions have use cases across diverse industries, including retail, consumer internet, healthcare, manufacturing, and financial services. Labelbox has a large portfolio of customers, including NASA's Jet Propulsion Laboratory and Blue River Technology, a smart AgriTech company that used Labelbox's model-assisted labeling suite to enhance its See &amp; Spray technology in smart agriculture, resulting in herbicide cost savings of 70%&ndash;80. Labelbox's customers also include several Fortune 500 companies, such as Walmart, P&amp;G, Audi Adobe, Airbnb, Bayer, and Bosch.
 
 
 Key partnerships include a long-term collaboration with 
 <a href="https://sp-edge.com/updates/21770">
 Google Cloud
 </a>
 to facilitate digital transformations in retail, consumer internet, financial services, and manufacturing and logistics.
 
 
 Funding and financials
 
 
 In January 2022, the firm raised USD 110 million in Series D funding led by SoftBank's Vision Fund 2. The company planned to utilize the funds to finance company expansion.
 
 
 
</div>

Labelbox

Integrated solutions that handle various processes such as model training, fine-tuning, model deployment, monitoring, and maintenance in working with and deploying LLMs

Platforms that provide hardware such as high-performance CPUs, GPUs, or TPUs, including cloud-based solutions that are commonly used to train and run GenAI models efficiently

Platforms that assist with fine-tuning pre-trained GenAI models or custom models tailored to specific use cases. Includes services that train models from scratch or use existing models

Platforms that store and retrieve training data in vector databases for access during the model training phase

Services to deploy GenAI models (on-premises or cloud-based) into production environments and integration tools to support existing systems and workflows

Ongoing monitoring of GenAI models to ensure performance. Includes regular model retraining, performance optimization, and troubleshooting

Platforms that assist in designing and refining prompts or instructions to GenAI models to get the desired responses or outcomes

Platforms that develop and implement strategies, policies, and practices to ensure the responsible, secure, ethical, and safe use of Generative AI technologies within an organization.

All services offered by these companies provide support to AI/ML

NLP is a key component of generative AI which is the core focus of this hub.

All companies within this space are offering infrastructure for generative AI

Generative AI infrastructure hub covers companies that deploy and run these foundation models.

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 Zilliz, responsible for the open-source vector database Milvus, has recently unveiled a significant enhancement to Zilliz Cloud, its vector database solution. This upgrade tackles issues related to escalating GenAI applications from prototype to full-scale production.
 New features introduced with this update include a vector migration service for efficient data transfer, integration with Fivetran for access to over 500 sources, enhanced scalability, automated visibility, and increased enterprise security through Auth0 Single Sign-On. Users can access Zilliz Cloud via their platform.
 According to Zilliz, these improvements will effectively simplify unstructured data management, improve overall performance, and equip developers with the necessary resources to construct and control GenAI applications at a larger scale.
</div> Analyst QuickTake: 
 Zilliz has been steadily expanding its reach and introducing new features to strengthen its position in the vector storage space. By <a href="https: 
//zilliz.com/blog/zilliz-cloud-available-in-11-regions-across-3-major-cloud-providers"> June 2024 </a> , Zilliz grew its global presence to 11 regions through AWS, Azure, and Google Cloud integrations. With the recent <a href="https: 
//www.globenewswire.com/en/news-release/2024/03/20/2849591/0/en/Zilliz-Introduces-Milvus-2-4-with-GPU-Indexing-Support-for-CAGRA.html"> launch </a> of Milvus 2.4 in March, Zilliz continues to boost its performance and reliability.

Zilliz

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless